Home
/
4D Molecular Therapeutics, Inc.
/
Financials
/
Quarterly
4D Molecular Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that 4D Molecular Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2024
$3.0K
Nov 13, 2024
Q2
2024
Jun 30, 2024
$5.0K
Aug 8, 2024
Q1
2024
Mar 31, 2024
$28.0K
May 9, 2024
Q3
2024
Sep 30, 2023
$20.20M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$239.0K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$298.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$500.0K
Nov 9, 2023
Q2
2023
Jun 30, 2022
$162.0K
Aug 9, 2023
Q1
2023
Mar 31, 2022
$1.22M
May 11, 2023
Q3
2022
Sep 30, 2021
$1.37M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$14.58M
Aug 11, 2022
Q1
2022
Mar 31, 2021
$2.00M
May 12, 2022
Q3
2021
Sep 30, 2020
$7.42M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$3.63M
Aug 12, 2021
Q1
2021
Mar 31, 2020
$3.54M
May 13, 2021
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$90.0K
Nov 10, 2025
Q2
2025
Jun 30, 2025
$15.0K
Aug 11, 2025
Q1
2025
Mar 31, 2025
$14.0K
May 8, 2025
Q3
2025
Sep 30, 2024
$3.0K
Nov 10, 2025
Q2
2025
Jun 30, 2024
$5.0K
Aug 11, 2025
Q1
2025
Mar 31, 2024
$28.0K
May 8, 2025
Q3
2024
Sep 30, 2023
$20.20M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$239.0K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$298.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$500.0K
Nov 9, 2023
Q2
2023
Jun 30, 2022
$162.0K
Aug 9, 2023
Q1
2023
Mar 31, 2022
$1.22M
May 11, 2023
Q3
2022
Sep 30, 2021
$1.37M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$14.58M
Aug 11, 2022
Q1
2022
Mar 31, 2021
$2.00M
May 12, 2022
Q3
2021
Sep 30, 2020
$7.42M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$3.51M
Aug 12, 2021
Q1
2021
Mar 31, 2020
$3.41M
May 13, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($56.88M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($54.66M)
Aug 11, 2025
Q3
2025
Jun 30, 2025
($54.66M)
Nov 10, 2025
Q2
2025
Mar 31, 2025
($47.97M)
Aug 11, 2025
Q3
2025
Mar 31, 2025
($47.97M)
Nov 10, 2025
Q1
2025
Mar 31, 2025
($47.97M)
May 8, 2025
Q3
2025
Sep 30, 2024
($43.84M)
Nov 10, 2025
Q3
2025
Jun 30, 2024
($34.95M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($34.95M)
Aug 11, 2025
Q2
2025
Mar 31, 2024
($32.40M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($32.40M)
May 8, 2025
Q3
2025
Mar 31, 2024
($32.40M)
Nov 10, 2025
Q3
2024
Sep 30, 2023
($10.26M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($29.62M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($29.62M)
Nov 13, 2024
Q3
2024
Mar 31, 2023
($28.68M)
Nov 13, 2024
Q1
2024
Mar 31, 2023
($28.68M)
May 9, 2024
Q2
2024
Mar 31, 2023
($28.68M)
Aug 8, 2024
Q3
2023
Sep 30, 2022
($25.69M)
Nov 9, 2023
Q3
2023
Jun 30, 2022
($28.09M)
Nov 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($61.19M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($59.46M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($53.62M)
May 8, 2025
Q3
2025
Sep 30, 2024
($51.13M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($42.46M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($38.14M)
May 8, 2025
Q3
2024
Sep 30, 2023
($13.97M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($32.14M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($30.11M)
May 9, 2024
Q3
2023
Sep 30, 2022
($26.50M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($28.43M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($26.39M)
May 11, 2023
Q3
2022
Sep 30, 2021
($22.66M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($7.60M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($16.31M)
May 12, 2022
Q3
2021
Sep 30, 2020
($7.82M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($15.15M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($13.28M)
May 13, 2021